| Interaction Color Code | Clinical Bottom Line | Clinical Effects | Drug 1 effect | Drug 2 dose | Drug 2 effect | Management | |
|---|---|---|---|---|---|---|---|
| Lenacapavir Quetiapine | Yellow: Adjust dosing | Minimal data to guide interaction: weigh risks and benefits of using this combination | Potential increased risk of quetiapine adverse effects (e.g. sedation, QT prolongation) |
Consider using alternative antipsychotics. If coadministering, consider quetiapine dose reduction and monitor for adverse effects. |
|||
| Darunavir Quetiapine 982 | Orange: Minimal data to guide interaction | Minimal data to guide interaction: risks likely to outweigh benefits | Potential for increased risk of quetiapine adverse effects |
Consider using alternative agents. If coadministering, reduce quetiapine dose to 1 / 6 of current dose and monitor for quetiapine adverse reactions |
|||
| Atazanavir Quetiapine 828 | Red: Avoid combination | Do not coadminister: Potential for increased levels of quentiapine. If coadministration is necessary: reduce dose to 1 / 6 of current dose. | Increased quentiapine effects. |
Contraindicated. Use alternative agents. |
|||
| Elvitegravir Quetiapine 234 | Orange: Minimal data to guide interaction | Minimal data to guide interaction: weigh risks and benefits of using this combination | Potential for increased risk of quetiapine adverse effects |
Consider alternative ARV therapy. For patients currently on elvitegravir / cobicistat: initiate quetiapine at lowest dose. Titrate accordingly and monitor for adverse effects. If patient already on quetiapine and requiring new elvitegravir / cobicistat: reduce queitapine to 1 / 6 of original dose before coadministering. Monitor efficacy and adverse effects. |
